Please assess the completion status of the following clinical trial:

Trial Title: Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known diagnosis of type 2 diabetes mellitus (T2DM) with glycosylated hemoglobin (HbA1c) between 6.5% and 10%, inclusive.~  * Stable doses of oral antihyperglycemic agents for at least 2 months~ * Stable dose of chronic insulin therapy for at least 2 months~ * HbA1c documented within 3 months before study enrollment~* Planned first elective coronary artery bypass graft (CABG) surgery~Exclusion Criteria:~* Elevated Creatine Kinase-Myocardial Bands (CK-MB) or troponin level above the 99th percentile at screening~* Receiving incretin therapy or having received incretin therapy within the previous 2 months~* Type 1 DM or a history of ketoacidosis~* Women who are pregnant or breastfeeding~* Known end-stage Kidney disease~* Known sensitivity or intolerance to saxagliptin or dipeptidyl peptidase-4 (DPP-4) inhibitor~* Clinically apparent liver disease~* History of pancreatitis

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin (Type: ACTIVE_COMPARATOR): Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).